The aim of the study was to compare the levels of fibroblast growth factor 23 (FGF23) and chemerin, as well as Vitamin D in psoriasis sufferers and healthy controls. From 2021 to 2022, ninety subjects were studied. The study comprised 45 individuals with psoriasis and 45 healthy controls. Serum fasting FGF23 and chemerin levels of the study group were examined by sandwich enzyme-linked immunosorbent assay. The results demonstrate that the mean serum FGF23 and chemerin quantities in psoriasis patients were greater than in controls, with a statistically significant. Patients with psoriasis, on the other hand, had considerably lower blood Vitamin D levels than healthy controls. These findings demonstrate that psoriatic patients have lower Vitamin D levels than healthy controls, and they add to the growing body of data linking FGF23, chemerin Vitamin D levels, and the course of psoriasis.